Prescription drug use in pregnancy

Susan E. Andrade, Jerry H. Gurwitz, Robert Davis, K. Arnold Chan, Jonathan A. Finkelstein, Kris Fortman, Heather McPhillips, Marsha A. Raebel, Douglas Roblin, David H. Smith, Marianne Ulcickas Yood, Abraham N. Morse, Richard Platt

Research output: Contribution to journalArticle

354 Citations (Scopus)

Abstract

Objective The purpose of this study was to provide information on the prevalence of the use of prescription drugs among pregnant women in the United States. Study design A retrospective study was conducted with the use of the automated databases of 8 health maintenance organizations that are involved in the Health Maintenance Research Network Center for Education and Research on Therapeutics. Women who delivered of an infant in a hospital from January 1, 1996, through December 31, 2000, were identified. Prescription drug use according to therapeutic class and the United States Food and Drug Administration risk classification system was evaluated, with the assumption of a gestational duration of 270 days, with three 90-day trimesters of pregnancy, and with a 90-day period before pregnancy. Nonprescription drug use was not assessed. Results During the period 1996 through 2000, 152,531 deliveries were identified that met the criteria for study. For 98,182 deliveries (64%), a drug other than a vitamin or mineral supplement was prescribed in the 270 days before delivery: 3595 women (2.4%) received a drug from category A; 76,292 women (50.0%) received a drug from category B; 57,604 women (37.8%) received a drug from category C; 7333 women (4.8%) received a drug from category D, and 6976 women (4.6%) received a drug from category X of the United States Food and Drug Administration risk classification system. Overall, 5157 women (3.4%) received a category D drug, and 1653 women (1.1%) received a category X drug after the initial prenatal care visit. Conclusion Our finding that almost one half of all pregnant women received prescription drugs from categories C, D, or X of the United States Food and Drug Administration risk classification system highlights the importance of the need to understand the effects of these medications on the developing fetus and on the pregnant woman.

Original languageEnglish (US)
Pages (from-to)398-407
Number of pages10
JournalAmerican Journal of Obstetrics and Gynecology
Volume191
Issue number2
DOIs
StatePublished - Aug 1 2004

Fingerprint

Prescription Drugs
Pregnancy
Pharmaceutical Preparations
United States Food and Drug Administration
Pregnant Women
Pregnancy Trimesters
Therapeutic Human Experimentation
Nonprescription Drugs
Prenatal Care
Health Maintenance Organizations
Vitamins
Minerals
Fetus
Retrospective Studies
Databases
Education
Health
Research

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Andrade, S. E., Gurwitz, J. H., Davis, R., Chan, K. A., Finkelstein, J. A., Fortman, K., ... Platt, R. (2004). Prescription drug use in pregnancy. American Journal of Obstetrics and Gynecology, 191(2), 398-407. https://doi.org/10.1016/j.ajog.2004.04.025

Prescription drug use in pregnancy. / Andrade, Susan E.; Gurwitz, Jerry H.; Davis, Robert; Chan, K. Arnold; Finkelstein, Jonathan A.; Fortman, Kris; McPhillips, Heather; Raebel, Marsha A.; Roblin, Douglas; Smith, David H.; Yood, Marianne Ulcickas; Morse, Abraham N.; Platt, Richard.

In: American Journal of Obstetrics and Gynecology, Vol. 191, No. 2, 01.08.2004, p. 398-407.

Research output: Contribution to journalArticle

Andrade, SE, Gurwitz, JH, Davis, R, Chan, KA, Finkelstein, JA, Fortman, K, McPhillips, H, Raebel, MA, Roblin, D, Smith, DH, Yood, MU, Morse, AN & Platt, R 2004, 'Prescription drug use in pregnancy', American Journal of Obstetrics and Gynecology, vol. 191, no. 2, pp. 398-407. https://doi.org/10.1016/j.ajog.2004.04.025
Andrade SE, Gurwitz JH, Davis R, Chan KA, Finkelstein JA, Fortman K et al. Prescription drug use in pregnancy. American Journal of Obstetrics and Gynecology. 2004 Aug 1;191(2):398-407. https://doi.org/10.1016/j.ajog.2004.04.025
Andrade, Susan E. ; Gurwitz, Jerry H. ; Davis, Robert ; Chan, K. Arnold ; Finkelstein, Jonathan A. ; Fortman, Kris ; McPhillips, Heather ; Raebel, Marsha A. ; Roblin, Douglas ; Smith, David H. ; Yood, Marianne Ulcickas ; Morse, Abraham N. ; Platt, Richard. / Prescription drug use in pregnancy. In: American Journal of Obstetrics and Gynecology. 2004 ; Vol. 191, No. 2. pp. 398-407.
@article{324f49a147ce4ff497d1270cae511b08,
title = "Prescription drug use in pregnancy",
abstract = "Objective The purpose of this study was to provide information on the prevalence of the use of prescription drugs among pregnant women in the United States. Study design A retrospective study was conducted with the use of the automated databases of 8 health maintenance organizations that are involved in the Health Maintenance Research Network Center for Education and Research on Therapeutics. Women who delivered of an infant in a hospital from January 1, 1996, through December 31, 2000, were identified. Prescription drug use according to therapeutic class and the United States Food and Drug Administration risk classification system was evaluated, with the assumption of a gestational duration of 270 days, with three 90-day trimesters of pregnancy, and with a 90-day period before pregnancy. Nonprescription drug use was not assessed. Results During the period 1996 through 2000, 152,531 deliveries were identified that met the criteria for study. For 98,182 deliveries (64{\%}), a drug other than a vitamin or mineral supplement was prescribed in the 270 days before delivery: 3595 women (2.4{\%}) received a drug from category A; 76,292 women (50.0{\%}) received a drug from category B; 57,604 women (37.8{\%}) received a drug from category C; 7333 women (4.8{\%}) received a drug from category D, and 6976 women (4.6{\%}) received a drug from category X of the United States Food and Drug Administration risk classification system. Overall, 5157 women (3.4{\%}) received a category D drug, and 1653 women (1.1{\%}) received a category X drug after the initial prenatal care visit. Conclusion Our finding that almost one half of all pregnant women received prescription drugs from categories C, D, or X of the United States Food and Drug Administration risk classification system highlights the importance of the need to understand the effects of these medications on the developing fetus and on the pregnant woman.",
author = "Andrade, {Susan E.} and Gurwitz, {Jerry H.} and Robert Davis and Chan, {K. Arnold} and Finkelstein, {Jonathan A.} and Kris Fortman and Heather McPhillips and Raebel, {Marsha A.} and Douglas Roblin and Smith, {David H.} and Yood, {Marianne Ulcickas} and Morse, {Abraham N.} and Richard Platt",
year = "2004",
month = "8",
day = "1",
doi = "10.1016/j.ajog.2004.04.025",
language = "English (US)",
volume = "191",
pages = "398--407",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Prescription drug use in pregnancy

AU - Andrade, Susan E.

AU - Gurwitz, Jerry H.

AU - Davis, Robert

AU - Chan, K. Arnold

AU - Finkelstein, Jonathan A.

AU - Fortman, Kris

AU - McPhillips, Heather

AU - Raebel, Marsha A.

AU - Roblin, Douglas

AU - Smith, David H.

AU - Yood, Marianne Ulcickas

AU - Morse, Abraham N.

AU - Platt, Richard

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Objective The purpose of this study was to provide information on the prevalence of the use of prescription drugs among pregnant women in the United States. Study design A retrospective study was conducted with the use of the automated databases of 8 health maintenance organizations that are involved in the Health Maintenance Research Network Center for Education and Research on Therapeutics. Women who delivered of an infant in a hospital from January 1, 1996, through December 31, 2000, were identified. Prescription drug use according to therapeutic class and the United States Food and Drug Administration risk classification system was evaluated, with the assumption of a gestational duration of 270 days, with three 90-day trimesters of pregnancy, and with a 90-day period before pregnancy. Nonprescription drug use was not assessed. Results During the period 1996 through 2000, 152,531 deliveries were identified that met the criteria for study. For 98,182 deliveries (64%), a drug other than a vitamin or mineral supplement was prescribed in the 270 days before delivery: 3595 women (2.4%) received a drug from category A; 76,292 women (50.0%) received a drug from category B; 57,604 women (37.8%) received a drug from category C; 7333 women (4.8%) received a drug from category D, and 6976 women (4.6%) received a drug from category X of the United States Food and Drug Administration risk classification system. Overall, 5157 women (3.4%) received a category D drug, and 1653 women (1.1%) received a category X drug after the initial prenatal care visit. Conclusion Our finding that almost one half of all pregnant women received prescription drugs from categories C, D, or X of the United States Food and Drug Administration risk classification system highlights the importance of the need to understand the effects of these medications on the developing fetus and on the pregnant woman.

AB - Objective The purpose of this study was to provide information on the prevalence of the use of prescription drugs among pregnant women in the United States. Study design A retrospective study was conducted with the use of the automated databases of 8 health maintenance organizations that are involved in the Health Maintenance Research Network Center for Education and Research on Therapeutics. Women who delivered of an infant in a hospital from January 1, 1996, through December 31, 2000, were identified. Prescription drug use according to therapeutic class and the United States Food and Drug Administration risk classification system was evaluated, with the assumption of a gestational duration of 270 days, with three 90-day trimesters of pregnancy, and with a 90-day period before pregnancy. Nonprescription drug use was not assessed. Results During the period 1996 through 2000, 152,531 deliveries were identified that met the criteria for study. For 98,182 deliveries (64%), a drug other than a vitamin or mineral supplement was prescribed in the 270 days before delivery: 3595 women (2.4%) received a drug from category A; 76,292 women (50.0%) received a drug from category B; 57,604 women (37.8%) received a drug from category C; 7333 women (4.8%) received a drug from category D, and 6976 women (4.6%) received a drug from category X of the United States Food and Drug Administration risk classification system. Overall, 5157 women (3.4%) received a category D drug, and 1653 women (1.1%) received a category X drug after the initial prenatal care visit. Conclusion Our finding that almost one half of all pregnant women received prescription drugs from categories C, D, or X of the United States Food and Drug Administration risk classification system highlights the importance of the need to understand the effects of these medications on the developing fetus and on the pregnant woman.

UR - http://www.scopus.com/inward/record.url?scp=4444259620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444259620&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2004.04.025

DO - 10.1016/j.ajog.2004.04.025

M3 - Article

VL - 191

SP - 398

EP - 407

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -